Valuation : HLS Therapeutics Inc.

Market Cap 82.73M 71.15M 66.92M 61.09M 114M 7.82B 115M 793M 307M 4.01B 311M 304M 12.76B P/E 2026 *
-12.9x
P/E 2027 * -38.2x
Enterprise Value 82.73M 71.15M 66.92M 61.09M 114M 7.82B 115M 793M 307M 4.01B 311M 304M 12.76B EV / Sales 2026 *
1.42x
EV / Sales 2027 * 1.27x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day+2.78%
1 week-1.33%
Current month-1.33%
1 month-8.19%
3 months-17.23%
6 months-15.14%
Current year-23.24%
1 week 3.58
Extreme 3.58
3.77
1 month 3.56
Extreme 3.56
4.12
Current year 3.56
Extreme 3.56
5.25
1 year 3.56
Extreme 3.56
5.76
3 years 3
Extreme 3
5.76
5 years 3
Extreme 3
20.52
10 years 3
Extreme 3
25.92
Manager TitleAgeSince
Chief Executive Officer 58 01/05/2023
Director of Finance/CFO 61 26/01/2024
Chief Tech/Sci/R&D Officer 61 01/06/2014
Director TitleAgeSince
Director/Board Member 58 12/03/2018
Chairman 48 22/06/2023
Director/Board Member 65 01/01/2021
Date Insider Type Main position Quantity % Market Cap. Importance
8/20/26 A Buy

Chief Executive Officer

500 0.0016%
8/17/26 A Buy

Chief Executive Officer

2,000 0.0064%
7/31/26 A TaxCompany 1,000 0.0032% -
Change 5-day change 1-year change 3-year change Capi.($)
+2.78%-1.33%-32.11%-20.77% 82.89M
-1.45%+2.56%+32.09%+116.90% 106B
-0.58%+5.35%+65.27%+179.02% 57.49B
-0.37%-1.11%-11.84%+262.16% 22.33B
-0.42%+1.85%-9.71%-4.83% 8.23B
-0.62%-0.22%-37.66%-26.92% 7.11B
+0.83%+1.53%+6.20%+28.66% 6.72B
+1.26%+3.82%-14.19%-26.80% 6.3B
+0.54%+0.18%-5.24%+19.96% 5.09B
+0.48%+8.51%+357.87%+481.22% 4.68B
Average +0.36%+1.94%+35.07%+100.86% 22.39B
Weighted average by Cap. -0.26%+2.51%+36.34%+136.97%

Financials

2026 *2027 *
Net sales 58.44M 50.26M 47.27M 43.15M 80.7M 5.53B 80.96M 560M 217M 2.83B 219M 215M 9.02B 65.03M 55.92M 52.6M 48.01M 89.8M 6.15B 90.09M 624M 241M 3.15B 244M 239M 10.03B
Net income -5.47M -4.7M -4.42M -4.04M -7.55M -517M -7.58M -52.46M -20.28M -265M -20.54M -20.09M -844M -2.16M -1.86M -1.75M -1.6M -2.99M -205M -3M -20.76M -8.02M -105M -8.13M -7.95M -334M
Net Debt - -
Logo HLS Therapeutics Inc.
HLS Therapeutics Inc. is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. It is engaged in addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease. Its products include Clozaril, CSAN Pronto, MyCare Psychiatry and Vascepa. Its Clozaril is an atypical antipsychotic indicated for the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules are a single-molecule prescription product for the treatment of cardiovascular disease.
Employees
85
Date Price Change Volume
04/09/26 CA$3.700 +2.78% 68,582
03/09/26 CA$3.600 -0.28% 17,951
02/09/26 CA$3.610 -3.73% 8,800
01/09/26 CA$3.750 0.00% 17,400
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.674USD
Average target price
5.286USD
Spread / Average Target
+97.66%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!